Guan Y - Search Results

1

Genomic Analysis of Circulating Tumor Cells at the Single-Cell Level.

Lu S, Chang CJ, Guan Y, Szafer-Glusman E, Punnoose E, Do A, Suttmann B, Gagnon R, Rodriguez A, Landers M, Spoerke J, Lackner MR, Xiao W, Wang Y. Lu S, et al. Among authors: guan y. J Mol Diagn. 2020 Jun;22(6):770-781. doi: 10.1016/j.jmoldx.2020.02.013. Epub 2020 Apr 2. J Mol Diagn. 2020. PMID: 32247862 Free PMC article.

2

High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic-Based Multiplex PCR and Next-Generation Sequencing.

Guan Y, Mayba O, Sandmann T, Lu S, Choi Y, Darbonne WC, Leveque V, Ryner L, Humke E, Tam NWR, Sujathasarma S, Cheung A, Bourgon R, Lackner MR, Wang Y. Guan Y, et al. J Mol Diagn. 2017 Nov;19(6):921-932. doi: 10.1016/j.jmoldx.2017.08.001. Epub 2017 Sep 1. J Mol Diagn. 2017. PMID: 28867605 Free article.

3

High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.

Bourgon R, Lu S, Yan Y, Lackner MR, Wang W, Weigman V, Wang D, Guan Y, Ryner L, Koeppen H, Patel R, Hampton GM, Amler LC, Wang Y. Bourgon R, et al. Among authors: guan y. Clin Cancer Res. 2014 Apr 15;20(8):2080-91. doi: 10.1158/1078-0432.CCR-13-3114. Epub 2014 Feb 26. Clin Cancer Res. 2014. PMID: 24573554

4

Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.

Ryner L, Guan Y, Firestein R, Xiao Y, Choi Y, Rabe C, Lu S, Fuentes E, Huw LY, Lackner MR, Fu L, Amler LC, Bais C, Wang Y. Ryner L, et al. Among authors: guan y. Clin Cancer Res. 2015 Jul 1;21(13):2941-51. doi: 10.1158/1078-0432.CCR-14-3111. Epub 2015 Apr 2. Clin Cancer Res. 2015. PMID: 25838397

5

Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer.

Hornburg M, Desbois M, Lu S, Guan Y, Lo AA, Kaufman S, Elrod A, Lotstein A, DesRochers TM, Munoz-Rodriguez JL, Wang X, Giltnane J, Mayba O, Turley SJ, Bourgon R, Daemen A, Wang Y. Hornburg M, et al. Among authors: guan y. Cancer Cell. 2021 Jul 12;39(7):928-944.e6. doi: 10.1016/j.ccell.2021.04.004. Epub 2021 May 6. Cancer Cell. 2021. PMID: 33961783 Free article.

6

Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance.

Wang Y, Lu LC, Guan Y, Ho MC, Lu S, Spahn J, Hsu CH. Wang Y, et al. Among authors: guan y. Exp Hematol Oncol. 2021 Aug 16;10(1):45. doi: 10.1186/s40164-021-00237-y. Exp Hematol Oncol. 2021. PMID: 34399826 Free PMC article.

7

Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer.

Desbois M, Udyavar AR, Ryner L, Kozlowski C, Guan Y, Dürrbaum M, Lu S, Fortin JP, Koeppen H, Ziai J, Chang CW, Keerthivasan S, Plante M, Bourgon R, Bais C, Hegde P, Daemen A, Turley S, Wang Y. Desbois M, et al. Among authors: guan y. Nat Commun. 2020 Nov 4;11(1):5583. doi: 10.1038/s41467-020-19408-2. Nat Commun. 2020. PMID: 33149148 Free PMC article.

8

A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Wagle M, Eiring AM, Wongchenko M, Lu S, Guan Y, Wang Y, Lackner M, Amler L, Hampton G, Deininger MW, O'Hare T, Yan Y. Wagle M, et al. Among authors: guan y. Leukemia. 2016 Jul;30(7):1493-501. doi: 10.1038/leu.2016.51. Epub 2016 Mar 8. Leukemia. 2016. PMID: 27044711 Free PMC article.

9

Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma.

Kaseb AO, Guan Y, Gok Yavuz B, Abbas AR, Lu S, Hasanov E, Toh HC, Verret W, Wang Y. Kaseb AO, et al. Among authors: guan y. J Hepatocell Carcinoma. 2022 Oct 11;9:1065-1079. doi: 10.2147/JHC.S369951. eCollection 2022. J Hepatocell Carcinoma. 2022. PMID: 36254201 Free PMC article.

10

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.

Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Zhu AX, et al. Among authors: guan y. Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23. Nat Med. 2022. PMID: 35739268

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,653 results

Search Page